laboratory medical geneticists, genetic counselors, 
medical educators, and the faculty of schools of med-
icine and other schools of health professions, on the 
following: 
‘‘(A) Pharmacogenomic testing and the ex-
tent of its ability to prevent adverse drug reac-
tions. 
‘‘(B) Pharmacogenomic testing, drug inter-
action alerting systems, when to refer to or con-
sult with a genetics provider, and the standards 
of care for patients who are suspected or known 
to have a genetic variant that is known to im-
pact drug metabolism. 
‘‘(C) 
Evidence-based 
information 
that 
would encourage individuals and their health 
care professionals to consider pharmacogenomic 
testing as part of their health care plan to the 
extent appropriate. 
‘‘(D) The role of medical professionals who 
specialize in genetics and genomics. 
‘‘(E) 
How 
to 
incorporate 
pharmacogenomics into comprehensive medica-
tion management. 
‘‘(2) GRANTS.— 
VerDate Sep 11 2014 
00:31 Mar 05, 2022
Jkt 029200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H6875.IH
H6875
kjohnson on DSK79L0C42PROD with BILLS
‘‘(A) AWARD.—In carrying out the na-
tional health education program under this sub-
section, the Secretary, acting through the Di-
rector of the National Human Genome Re-
search Institute, may award grants to nonprofit 
organizations to carry out educational activities 
with respect to the topics listed in subpara-
graphs (A) through (D) of paragraph (1). 
‘‘(B) USE OF FUNDS.—A grant under sub-
paragraph (A) may be used to support one or 
more of the following activities: 
‘‘(i) Increasing the knowledge and 
awareness of health care providers and 
health 
care 
leaders 
about 
pharmacogenomic testing and drug inter-
actions. 
‘‘(ii) Increasing the number of health 
professional 
schools 
that 
incorporate 
pharmacogenomic curricula in classroom 
instruction. 
‘‘(iii) Increasing the ability of health 
care providers to note and respond to the 
impact of gender, ethnicity, age, and other 
relevant characteristics on drug metabo-
lism. 
VerDate Sep 11 2014 
00:31 Mar 05, 2022
Jkt 029200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H6875.IH
H6875
kjohnson on DSK79L0C42PROD with BILLS
‘‘(iv) Developing principles, practices, 
and curriculum instruction that prepare 
medical, nursing, pharmacy, and other 
health professions students to effectively 
apply knowledge and skills needed to rec-
ognize— 
‘‘(I) when a patient is eligible for 
pharmacogenomic testing, including 
as part of comprehensive medication 
management when appropriate, and in 
accordance with the patient’s health 
care team, a drug product’s label, and 
professional clinical guidelines; and 
‘‘(II) how to appropriately use 
the test results to adjust a prescrip-
tion or otherwise change a patient’s 
health care plan. 
‘‘(v) Providing opportunities for prac-
ticing health care professionals to receive 
pharmacogenomics training and education 
through a variety of modalities including 
in-person, electronic media, professional 
meetings and conferences, and social 
media. 
VerDate Sep 11 2014 
00:31 Mar 05, 2022
Jkt 029200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H6875.IH
H6875
kjohnson on DSK79L0C42PROD with BILLS